第九版临床TNM分类中HPV相关口咽癌分期提案
这项国际多中心回顾性预后队列研究基于4家机构2053例HPV阳性口咽癌患者,评估治疗前淋巴结特征对预后的重要性。影像检测的结外延伸(iENE)是最强预后淋巴结特征(AHR 2.43,95%CI 1.96-3.03),将iENE阳性病例N分类上调1个层级的新分期方案在无病生存和总生存上优于现行TNM分期系统,并在独立数据集(n=451)中验证。
要点
- iENE阳性是HPV阳性口咽癌最强的预后淋巴结特征,ICON-N数据集AHR为2.43(95%CI 1.96-3.03)。
- 将iENE阳性病例N分类上调1个层级的新分期方案总体归一化评分优于现行TNM系统(2 vs 3)。
- 新分期方案在无病生存和总生存的风险分层上优于现行UICC/AJCC第八版TNM分期系统。
核心结论
- 将iENE阳性疾病的每个N类别上调1个层级,可改善无病生存和总生存。
- 所提新分类在风险分层上优于现行TNM分期系统,可能有助于未来临床试验设计、结局研究和患者照护。
研究设计与样本
- 国际多中心回顾性预后队列研究,纳入4家机构经根治性治疗的HPV阳性口咽癌患者(ICON-N数据集)。
- ICON-N数据集共2053例患者,其中cN阳性1898例(92.5%)、cN0 155例(7.5%);女性298例(14.5%);平均(SD)年龄60.6(9.3)岁。
- 独立数据集CHUM(n=451)用于验证所提分期方案。
- 神经放射科医师审阅治疗前CT和/或MRI评估淋巴结特征,包括异常淋巴结有无、咽后淋巴结、侧别、异常淋巴结数目及影像检测的结外延伸(iENE)。
- 数据收集于2023年2月至5月,分析于2023年6月至7月;中位(范围)随访5.1(0.1-14.7)年。
主要发现
- cN阳性患者中iENE阳性者为710/1898例(37.4%)。
- 多变量分析中iENE是最强预后淋巴结特征,iENE阳性vs iENE阴性(原文写作iENE-positive vs iENE-positive)的AHR在ICON-N数据集为2.43(95%CI 1.96-3.03),在CHUM数据集为2.04(95%CI 1.28-3.23)。
- 将iENE阳性病例N分类上调1个层级而不改变iENE阴性病例,所得AHR分期方案在无病生存和总生存上优于现行TNM分期系统,总体归一化评分更低(即更好)(2 vs 3)。
关键数值与推荐
- iENE阳性vs iENE阴性的AHR:ICON-N数据集2.43(95%CI 1.96-3.03),CHUM数据集2.04(95%CI 1.28-3.23)。
- AHR分期方案总体归一化评分为2,现行TNM分期系统为3(评分越低越好)。
- iENE阳性病例N分类上调1个层级,iENE阴性病例不变。
临床怎么用
- 作者认为所提新分类可能有助于未来临床试验设计、结局研究和患者照护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A subset of Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) eighth edition TNM stage I and II human papillomavirus-positive oropharyngeal carcinoma has undesirable outcomes, which might have contributed to a lack of success in phase III deintensification trials. Refining clinical stage groups, especially in the overabundant cN1/stage I group, has become important for treatment selection. OBJECTIVE: To assess the prognostic importance of pretreatment lymph node (LN) characteristics to optimize case distribution and outcome homogeneity within the N classification system. DESIGN, SETTING, AND PARTICIPANTS: This is an international multi-institutional retrospective prognostic cohort study. Analysis of human papillomavirus-positive oropharyngeal carcinoma treated curatively from 4 institutions (International Collaboration of Oropharyngeal Cancer Network for N-Classification [ICON-N] dataset) provided a refined clinical staging proposal; an independent dataset (Centre Hospitalier de l'Université de Montréal [CHUM] dataset) validated the proposal. Neuroradiologists reviewed pretreatment computed tomography and/or magnetic resonance imaging for nodal features, including presence or absence of abnormal LN(s), retropharyngeal LN, laterality, number of abnormal LN, and imaging-detected extranodal extension (iENE). Data were collected from February to May 2023, and data were analyzed from June to July 2023. EXPOSURES: Definitive chemoradiotherapy/radiotherapy or definitive surgery with or without postoperative chemoradiotherapy/radiotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival. A Cox proportional hazards multivariable model was used to estimate adjusted hazard ratios (AHRs) and to derive an optimal clinical TNM stage classification (AHR-stage schema) incorporating the strongest prognostic nodal features within the UICC/AJCC eighth edition TNM framework after confirming the prognostication of iENE status. The performance (according to overall normalized scores and ranking) of the AHR-stage schema against the current UICC/AJCC eighth edition TNM staging system was evaluated for hazard consistency, hazard discrimination, prognostic importance, and sample size balance. Validation was performed in the CHUM dataset. RESULTS: The ICON-N dataset comprised 2053 patients, including 1898 (92.5%) with cN-positive disease and 155 (7.5%) with cN0 disease; a total of 298 (14.5%) were female, and the mean (SD) age was 60.6 (9.3) years. iENE-positive disease was identified in 710 of 1898 patients with cN-positive disease (37.4%). The median (range) follow-up was 5.1 (0.1-14.7) years. iENE was the strongest prognostic nodal feature in multivariable analysis; the AHR for iENE-positive vs iENE-positive disease was 2.43 (95% CI, 1.96-3.03) in the ICON-N dataset and 2.04 (95% CI, 1.28-3.23) in the CHUM dataset (n = 451). Reclassifying iENE-positive cases 1 stratum higher for N categorization without altering iENE-negative cases yielded an AHR-stage schema that outperformed the current TNM staging system in disease-free and overall survival with a lower (ie, better) overall normalized score (2 vs 3). CONCLUSIONS AND RELEVANCE: In this study, reclassifying each N category 1 stratum higher for iENE-positive disease resulted in better disease-free and overall survival. The proposed new classification outperformed the currently TNM staging system in risk stratification and may facilitate future clinical trial design, outcomes research, and patient care.
引用
- Huang SH, Su J, Koyfman SA, et al. A Proposal for HPV-Associated Oropharyngeal Carcinoma in the Ninth Edition Clinical TNM Classification. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40338536. doi:10.1001/jamaoto.2025.0848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。